These results provide rationale for combination therapies, with CAR-T cells and checkpoint blockade, as a new strategy to overcome the tumor escape and to further strengthen CAR-T cells, especially in patients with PDAC shown to express high levels of PD-L1. The gene discussed is CD274; the disease is neoplasm.